A crackdown on DEI-related hiring policies from the Trump administration has triggered doubts about how agencies like the FDA will monitor and enforce diversity in clinical trials. Explore how pharma giants are refining diversity goals in R&D and navigating a politically-charged landscape in this Trendline.
|
|
|
-
FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.
-
What should pharma make of the FDA going dark on DEI?
-
Will the ‘anti-woke’ movement derail DEI efforts in pharma?
|
|
This Trendline is independently produced by our journalists. The support of our sponsors makes this journalism possible. Want to learn about sponsorship opportunities? Contact us directly at advertising@industrydive.com.
|
|
|
|
